Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFER | P55789 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 4/20 | 0.46 |
| ▸ | MAOA | P21397 | 2/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | FDPS | P14324 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.41 |
| ▸ | ESRRG | P62508 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24309600 | 0.78 | ESR1 (0.54) | ALDH1A1CYP3A4TDP1SIGMAR1LMNA | |
| SCHEMBL2034098 | 0.77 | GFER (0.46) | GFERMAOBMAOARECQLFDPS | |
| SCHEMBL2029489 | 0.76 | GFER (0.46) | GFERMAOBMAOARECQLFDPS | |
| SCHEMBL24309599 | 0.75 | TAAR1 (0.53) | MAOBALDH1A1TSHRSIGMAR1 | |
| SCHEMBL7393069 | 0.75 | GFER (0.45) | GFERMAOBMAOARECQLFDPS | |
| SCHEMBL8164156 | 0.72 | GFER (1.00) | GFERMAOBMAOARECQLALDH1A1 | |
| SCHEMBL3482833 | 0.72 | GFER (1.00) | GFERMAOBMAOARECQLALDH1A1 | |
| SCHEMBL187043 | 0.72 | GFER (1.00) | GFERMAOBMAOARECQLALDH1A1 | |
| SCHEMBL9440568 | 0.72 | GFER (0.46) | GFERMAOBMAOARECQLFDPS | |
| Phosphonic Acid SCHEMBL9358379 | 0.72 | GFER (0.46) | GFERMAOBMAOARECQLFDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137086-A1 | METHODS TO REDUCE CONTAMINATION, BIOFILM AND FOULING FROM WATER SYSTEMS, SURFACES, AND PRODUCTS | AEQUOR INC. (US) | 2026-05-21 | — | — | US | claimed |
| WO-2023250347-A1 | METHODS TO REDUCE CONTAMINATION, BIOFILM, AND FOULING FROM WATER SYSTEMS AND SURFACES | AEQUOR, INC. (US) | 2023-12-28 | — | — | WO | claimed |
| US-20230371517-A1 | COMBINATIONS TREATMENTS | AEQUOR, INC. (US) | 2023-11-23 | — | — | US | claimed |
| US-20220322671-A1 | METHODS TO REDUCE CONTAMINATION, BIOFILM AND FOULING FROM WATER SYSTEMS, SURFACES, AND PRODUCTS | AEQUOR, INC. (US) | 2022-10-13 | — | — | US | claimed |
| WO-2022081594-A1 | ANTIMICROBIAL COMBINATION THERAPEUTICS | AEQUOR, INC. (US) | 2022-04-21 | — | — | WO | claimed |
| US-20260137086-A1 | METHODS TO REDUCE CONTAMINATION, BIOFILM AND FOULING FROM WATER SYSTEMS, SURFACES, AND PRODUCTS | AEQUOR INC. (US) | 2026-05-21 | — | — | US | disclosed |
| WO-2023250347-A1 | METHODS TO REDUCE CONTAMINATION, BIOFILM, AND FOULING FROM WATER SYSTEMS AND SURFACES | AEQUOR, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| US-20230371517-A1 | COMBINATIONS TREATMENTS | AEQUOR, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| US-20220322671-A1 | METHODS TO REDUCE CONTAMINATION, BIOFILM AND FOULING FROM WATER SYSTEMS, SURFACES, AND PRODUCTS | AEQUOR, INC. (US) | 2022-10-13 | — | — | US | disclosed |
| WO-2022081594-A1 | ANTIMICROBIAL COMBINATION THERAPEUTICS | AEQUOR, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230371517-A1 | COMBINATIONS TREATMENTS | DDT, AS3MT, GPX4 | GFER 663/4885MAOB 2174/4885MAOA 2552/4885 |
| US-20260137086-A1 | METHODS TO REDUCE CONTAMINATION, BIOFILM AND FOULING FROM WATER SYSTEMS, SURFACES, AND PRODUCTS | GRHPR, HAO2, CBR1 | GFER 86/4885MAOB 3841/4885MAOA 2971/4885 |
| US-20220322671-A1 | METHODS TO REDUCE CONTAMINATION, BIOFILM AND FOULING FROM WATER SYSTEMS, SURFACES, AND PRODUCTS | PFAS, ERG28, DDT | GFER 289/4885MAOB 1771/4885MAOA 2172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.